ArticleESMO open2026

Adjuvant pembrolizumab plus belzutifan versus placebo in clear cell renal cell carcinoma: a reconstructed survival data analysis of the KEYNOTE-564 and the LITESPARK-022 trials.

A Cigliola et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.